dc.contributor.author | Delgado Álvarez, Elías | |
dc.contributor.author | Jodar, Esteban | |
dc.contributor.author | Mezquita Raya, Pedro | |
dc.contributor.author | Moreno Pérez, Óscar | |
dc.date.accessioned | 2022-11-08T12:43:00Z | |
dc.date.available | 2022-11-08T12:43:00Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Diabetes Therapy, 13(Suppl. 1), p. 19-34 (2022); doi:10.1007/s13300-022-01278-0 | |
dc.identifier.issn | 1869-6953 | |
dc.identifier.issn | 1869-6961 | |
dc.identifier.uri | http://hdl.handle.net/10651/65392 | |
dc.description.sponsorship | AstraZeneca | |
dc.format.extent | p. 19-34 | |
dc.language.iso | eng | |
dc.relation.ispartof | Diabetes Therapy | |
dc.rights | © 2022 Los autores | |
dc.rights | CC Reconocimiento 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | WOS:000811438400002 | |
dc.title | Benefits of SGLT2i for the treatment of heart failure irrespective of diabetes diagnosis: a state-of-the-art review | |
dc.type | journal article | |
dc.identifier.doi | 10.1007/s13300-022-01278-0 | |
dc.relation.publisherversion | http://dx.doi.org/10.1007/s13300-022-01278-0 | |
dc.rights.accessRights | open access | |
dc.type.hasVersion | VoR | |